Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Annals of the American Thoracic Society|February 16, 2024
Nintedanib plus Chemotherapy for Small Cell Lung Cancer with Comorbid Idiopathic Pulmonary FibrosisSatoshi Ikeda, Takashi Ogura, Terufumi Kato, et al.
Cancer Medicine|June 3, 2023
Prophylactic treatment of dacomitinib-induced skin toxicities in epidermal growth factor receptor-mutated non-small-cell lung cancer: A multicenter, Phase II trialMasahiro Iwasaku, Junji Uchino, Kenji Chibana, et al.
The Oncologist|October 1, 2022
A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 StudyYusuke Chihara, Takayuki Takeda, Yasuhiro Goto, et al.
Thoracic Cancer|June 30, 2025
Significance of Platinum-Based Chemotherapy With Programmed Death-1 Blockade in Limited Disease Small Cell Lung Cancer: A Retrospective StudyAyako Shiono, Hisao Imai, Kyoichi Kaira, et al.
Cancer Treatment and Research Communications|June 4, 2025
Plasma biomarkers for afatinib monotherapy in EGFR-mutated non-small cell lung cancer: Novel insights from companion genomics analysis of the EXTRA studyTomonori Makiguchi, Hisashi Tanaka, Kei Morikawa, et al.
Therapeutic Advances in Medical Oncology|August 4, 2022
Prospective analysis of factors precluding the initiation of durvalumab from an interim analysis of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study)Shigeru Tanzawa, Tomonori Makiguchi, Sadatomo Tasaka, et al.
Therapeutic Advances in Medical Oncology|December 26, 2022
A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study): primary analysisHisashi Tanaka, Shigeru Tanzawa, Toshihiro Misumi, et al.
JTO Clinical and Research Reports|December 4, 2023
Multicenter, Retrospective Study to Evaluate Necitumumab Plus Cisplatin and Gemcitabine After Immune Checkpoint Inhibitors in Advanced Squamous Cell Lung Cancer in Japan: The NINJA StudyYasunori Murata, Shigeru Tanzawa, Toshihiro Misumi, et al.
Therapeutic Advances in Medical Oncology|February 17, 2025
Clinical impact of hypomagnesemia induced by necitumumab plus cisplatin and gemcitabine treatment in patients with advanced lung squamous cell carcinoma: a subanalysis of the NINJA studyShigeru Tanzawa, Hiroshige Yoshioka, Toshihiro Misumi, et al.
Therapeutic Advances in Medical Oncology|March 17, 2025
Skin disorder within 30 days is a favorable prognostic factor in patients with lung squamous cell carcinoma treated with necitumumab plus gemcitabine and cisplatin: a sub-analysis of the NINJA studyFumihiko Kinoshita, Shigeru Tanzawa, Toshihiro Misumi, et al.
Pageof 4